Mauna Kea Technologies announced that 5 communications supporting Cellvizio® were presented during the recent European Respiratory Society (ERS) International Congress 2021. These presentations focused on the safety, efficacy, and feasibility of Cellvizio when used with manual and robotic-assisted bronchoscopy, fine-tuning sampling location and reduction of the bronchoscopic near-miss rate, and the application of Cellvizio in detecting fibrotic changes in vivo in patients diagnosed with COVID-19. The first results of the clinical study, co-funded by the Lung Cancer Initiative (LCI) at Johnson & Johnson, combines needle-based confocal laser endomicroscopy and robotic-assisted bronchoscopy using both Cellvizio and the Monarch® Platform from Auris Health Inc. to aid in diagnosing peripheral lung nodules. As detailed in the study presentation during the ERS International Congress, one patient with a malignant nCLE image but a negative result during robotic-assisted bronchoscopic lesion sampling was diagnosed with malignancy after surgery, and in 6/17 (35%) of patients, nCLE guidance resulted in readjustment of the robotic bronchoscope with optimization of the sampling location.